URGN_OUT_1 [2025-04-28 14:28:00 -0400] 6904 Bytes | 1912 tokens | Cum: 1912 tkns (23.90% of 8k)
==========================================================================

We're scouting for winners today. Its 2:27 PM on Mon Apr 28, 2025 and I'm looking at UroGen Pharma (URGN) up to $11.51 from $9.87

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: UroGen Pharma (URGN)
IPO: 2017-05-04 (7 Years Ago)
Market Cap: $446,423,799
Shares Outstanding: 46,090,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Here’s a list of headlines for UroGen Pharma:

Apr-27-25 04:00PM - OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
Apr-27-25 04:00PM 01:00PM - New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
Apr-27-25 04:00PM 12:30PM - New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
Apr-26-25 06:30PM - UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
Apr-26-25 06:30PM 10:00AM - UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
Apr-14-25 08:00AM - UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
Apr-12-25 10:02AM - UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy
Mar-12-25 03:00PM - UroGen Pharma Ltd (URGN) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial ...
Mar-10-25 09:10AM - Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates
Mar-10-25 09:10AM 08:00AM - UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
Mar-07-25 08:00AM - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb-27-25 08:00AM - UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
Feb-25-25 12:30PM - Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?
Feb-24-25 04:00PM - UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
Feb-21-25 10:53AM - UroGen acquires IconOVirs oncolytic virus assets
Feb-20-25 08:00AM - UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
Feb-14-25 02:30PM - UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
Feb-12-25 08:00AM - Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
Jan-30-25 08:00AM - UroGen Pharma to Present at Upcoming Investor Conferences
Jan-22-25 08:00AM - New Real-World Durability of Response Data for JELMYTO Reports 68% Recurrence-Free Survival Rate (RFS) at Three Years Across a Broad Patient Population with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)
Jan-15-25 08:00AM - ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months Paving the Way for the Potential First FDA-Approved Treatment for LG-IR-NMIBC in June 2025
Dec-06-24 08:00AM - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-03-04T18:00:00Z - BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight
B2 - 2024-06-17T20:46:00Z - UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
B3 - 2024-06-17T09:00:00Z - Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
B4 - 2024-06-14T12:30:33Z - Hasbro To Rally Around 38%? Here Are 10 Top Analyst Forecasts For Friday
B5 - 2024-04-22T09:29:00Z - Pharming Group (PHAR) Surges 7.2%: Is This an Indication of Further Gains?
B6 - 2024-03-25T18:44:08Z - Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for UroGen Pharma (URGN).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

URGN_OUT_3 [2025-04-28 14:28:01 -0400] 1181 Bytes | 310 tokens | Cum: 2224 tkns (27.80% of 8k)
==========================================================================

Showing B2 (chunk 1 of 2): B2:
**UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/17/2900031/0/en/UroGen-Pharma-Announces-Commencement-of-Public-Offering-of-Ordinary-Shares-and-Pre-Funded-Warrants.htmlPRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell its ordinary shares and pre-funded warrants. In connection with the proposed offering, UroGen also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the total number of ordinary shares (including

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_5 [2025-04-28 14:28:02 -0400] 615 Bytes | 150 tokens | Cum: 2376 tkns (29.70% of 8k)
==========================================================================

Showing B2 (chunk 2 of 2): those underlying pre-funded warrants) offered in the public offering. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. All of the ordinary shares and pre-funded warrants to be sold in the proposed offering will be offered by UroGen.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_7 [2025-04-28 14:28:02 -0400] 938 Bytes | 279 tokens | Cum: 2657 tkns (33.21% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T17:51:04Z - UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For B...
A2 - 2025-04-28T14:27:14Z - Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday - ADMA ...
A3 - 2025-04-28T05:08:56Z - UroGen Pharma announces long-term follow up data from OPTIMA II Phase 2b study...
A4 - 2025-04-28T05:08:56Z - UroGen Pharma reports long-term follow-up study with JELMYTO...
A5 - 2025-04-28T05:08:56Z - UroGen Pharma announces results from Phase 1 study of UGN-301...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

URGN_OUT_9 [2025-04-28 14:28:03 -0400] 1181 Bytes | 333 tokens | Cum: 2992 tkns (37.40% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - UroGen Pharma (NASDAQ:URGN)**Date: 2025-04-28Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/general/biotech/25/04/45047962/urogen-pharma-touts-four-year-response-with-urothelial-cancer-drug-study-highlights-potential-for-bladder-cancer-candidatesUroGen Pharma Ltd. URGN on Sunday highlighted a duration of response of nearly four years from a long-term follow-up study with Jelmyto (mitomycin) for pyelocalyceal solution.

The U.S. Food And Drug Administration approved Jelmyto in 2020 for low-grade upper tract urothelial cancer (LG-UTUC) in adults.

Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with Jelmyto (n = 41), the median duration of response was 47

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_11 [2025-04-28 14:28:07 -0400] 1183 Bytes | 282 tokens | Cum: 3276 tkns (40.95% of 8k)
==========================================================================

Showing A1 (chunk 2 of 6): .8 months, regardless of whether their cancer was new onset or recurrent (median follow-up, 28.1 months).

Of these patients, 21 had new-onset UTUC, and 20 had recurrent UTUC at baseline. There were no significant differences in durability between the groups, with eight patients in each group experiencing recurrence or death not due to treatment.

20 patients entered long-term follow-up.

To further explore Jelmyto's potential in treating patients with LG-UTUC, investigators are now enrolling participants in the Jelmyto uTRACT Registry to gather longitudinal real-world usage data. As of April 2025, 22 sites have been activated and 251 patients have been enrolled.

On Sunday, UroGen Pharma also announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for an intravesical solution.

The data demonstrated a clinically meaningful two-year duration of response (24.2 months).

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_13 [2025-04-28 14:28:07 -0400] 1181 Bytes | 297 tokens | Cum: 3575 tkns (44.69% of 8k)
==========================================================================

Showing A1 (chunk 3 of 6):

UGN-102 is UroGen's sustained-release formulation of mitomycin, being developed for recurrent low-grade, intermediate-risk, non-muscle-invasive bladder cancer (LG-IR-NMIBC).

Among the 41 patients achieving a complete response (CR) at three months, 25 remained in CR at 12 months, and 17 of these patients entered long-term follow-up.

The median duration of response for the 41 patients who achieved CR was 24.2 months, with a median follow-up time of 33.6 months. Twenty patients (48.8%) experienced recurrence of low-grade disease.

One patient progressed to a high-grade disease, and one patient died due to a cardiac disorder. Five patients remained disease-free at the time of the four-year data analysis.

UroGen completed the submission of the UGN-102 rolling new drug application (NDA) to the FDA for UGN-102 in August 2024. The FDA accepted the NDA for UGN-102 with a Prescription Drug Us

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_15 [2025-04-28 14:28:08 -0400] 1181 Bytes | 307 tokens | Cum: 3884 tkns (48.55% of 8k)
==========================================================================

Showing A1 (chunk 4 of 6): er Free Act (PDUFA) goal date of June 13, 2025.

UroGen Pharma also shared an updated 18-month DOR of 80.6% from the Phase 3 ENVISION trial of UGN-102 (mitomycin) for the intravesical solution, an investigational treatment for recurrent LG-IR-NMIBC.

On Friday, UroGen Pharma shared safety data from the Phase 1 dose-escalation study for UGN-301 (zalifrelimab) intravesical solution for recurrent non-muscle invasive bladder cancer.

The study included up to 30 patients per arm and aimed to assess safety and determine the recommended Phase 2 dose of UGN-301 as monotherapy and in combination with other agents.

In the monotherapy arm, dose escalation continued to the maximum feasible dose. No dose-limiting toxicities or treatment-emergent adverse events leading to treatment discontinuation were observed.

Among evaluable patients who received UGN-301, 46% of those with Ta/T1 disease and 33% w

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_17 [2025-04-28 14:28:09 -0400] 1182 Bytes | 302 tokens | Cum: 4188 tkns (52.35% of 8k)
==========================================================================

Showing A1 (chunk 5 of 6): ith carcinoma in situ (CIS) ± Ta/T1 disease were recurrence-free or had achieved a complete response at week 12.

At the 15-month disease assessment, 60% of patients with Ta/T1 disease treated with 300 mg remained recurrence-free, including one with high-grade T1 disease.

In the 500 mg cohort, 25% of patients with CIS disease and 33% of patients with Ta/T1 disease remained disease-free at six months; both are still active participants in the study.

D.Boral Capital analyst Jason Kolbert writes, "These data position UGN-301 as a promising candidate for a population in urgent need of more localized, immunomodulatory therapies..."

Price Action: URGN stock is up 7.65% at $10.63 at the last check Monday.

Read Next:

Roper Lifts 2025 Guidance After Solid Q1, CEO Sees Growth Ahead Despite Economic Uncertainty

Photo: Shutterstock

URGNUroGen Pharma Ltd$11.0111.6%Stock Score Locked: Want to S

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_19 [2025-04-28 14:28:10 -0400] 511 Bytes | 140 tokens | Cum: 4330 tkns (54.12% of 8k)
==========================================================================

Showing A1 (chunk 6 of 6): ee it?

Benzinga Rankings give you vital metrics on any stock - anytime.

Reveal Full ScoreEdge RankingsMomentum22.52Growth-Quality-Value20.87Price TrendShortMediumLongOverviewMarket News and Data brought to you by Benzinga APIs

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_21 [2025-04-28 14:28:11 -0400] 1105 Bytes | 295 tokens | Cum: 4627 tkns (57.84% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-10 10-K Item 7. Management s Discussion and Analysis of Fin Cond and Results of Oper

The following discussion contains management s discussion and analysis of our financial condition and results of operations and should be read together with the historical consolidate...

S2 - 2025-03-10 8-K Item 2.02

Results of Oper and Fin Cond

On March 10, 2025, UroGen Pharma Ltd. (the Company) announced its financial results for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1.

The information in th...

S3 - 2025-02-20 8-K Item1.01Entry into a Material Definitive Agrmt.

On February 14, 2025 (the Closing Date), UroGen Pharma Ltd. (the Company) and UroGen Pharma, Inc. (Purchaser) entered into an Asset Purchase Agrmt (the Agrmt) with IconOVir Bio, Inc. (IconOVir), pursuant to which Purch...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

URGN_OUT_23 [2025-04-28 14:28:11 -0400] 1181 Bytes | 228 tokens | Cum: 4857 tkns (60.71% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Management s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion contains management s discussion and analysis of our financial condition and results of operations and should be read together with the historical consolidated financial statements and the notes thereto included in Financial Statements and Supplementary Data. This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in the Risk Factors section of this Annual Report. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read Special Note Regarding Forward-Looking Statements and Risk Factors.

Overview

We are a biotechnology company dedicated to developing and commercializing

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_25 [2025-04-28 14:28:12 -0400] 1181 Bytes | 288 tokens | Cum: 5147 tkns (64.34% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our approved product Jelmyto (mitomycin) for pyelocalyceal solution, and our investigational candidates, UGN-102 (mitomycin) for intravesical solution, UGN-103 (mitomycin) for intravesical solution and UGN-104 (mitomycin) for pyelocalyceal solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer (low-grade UTUC) in the case of Jelmyto and UGN-104 and low-grade

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_27 [2025-04-28 14:28:14 -0400] 1181 Bytes | 291 tokens | Cum: 5440 tkns (68.00% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): intermediate risk non-muscle invasive bladder cancer (low-grade intermediate risk NMIBC)in the case of UGN-102 and UGN-103. In addition, our immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, which we are currently studying as both monotherapy and combination therapy.

If approved, UGN-102 would become the first U.S. Food and Drug Administration ("FDA") approved medicine for low-grade intermediate risk NMIBC. We estimate that the annual treatable population of low-grade intermediate risk NMIBC in the United States is approximately 82,000, of which approximately 23,000 are estimated to be newly diagnosed and 59,000 are estimated to be recurrent patients. We estimate that the total addressable market opportunity for UGN-102 in low-grade intermediate risk NMIBC is potentially over $5.0 billion, assuming an expected pricing range of $16,000 to $19,000 per

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_29 [2025-04-28 14:28:15 -0400] 1181 Bytes | 275 tokens | Cum: 5717 tkns (71.46% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): dose.

UGN-102, if approved, may be an alternative to the current standard of care for low-grade intermediate risk NMIBC, trans-urethral resection of bladder tumor (TURBT). We estimate that approximately 68% of low-grade intermediate risk NMIBC patients have two or more recurrences, with approximately 23% of recurrent patients having five or more recurrences. Repeated TURBT procedures to treat these recurrences can impact patients physical health and quality of life. We estimate that around 35% of patients will experience an adverse event within 90 days of undergoing a TURBT, and patients who have had two to four procedures have an estimated 14% greater risk of death than patients who have only had one procedure.

RTGel is a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology, which, unlike the general characteristics of most forms of matter, is liqui

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_31 [2025-04-28 14:28:15 -0400] 1181 Bytes | 256 tokens | Cum: 5975 tkns (74.69% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): d at lower temperatures and converts into gel form when warmed to body temperature. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urinary tract, forming a transient reservoir of drug that dissolves over time while preventing rapid excretion, providing for increased dwell time. RTGel leverages the physiologic flow of urine to provide a natural exit from the body.

We believe that RTGel , when formulated with an active drug, may allow for the improved efficacy of treatment of various types of urothelial and specialty cancers and urologic diseases without compromising the safety of the patient or interfering with the natural flow of fluids in the urinary tract. RTGel achieves this by:

##TABLE_START

increasing the exposure of active drugs in the bladder and upper urinary tract by significant

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_33 [2025-04-28 14:28:16 -0400] 790 Bytes | 184 tokens | Cum: 6161 tkns (77.01% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): ly extending the dwell time of the active drug while conforming to the anatomy of the bladder and the upper urinary tract, which allows for enhanced drug tissue coverage. For example, the average dwell time of the standard aqueous mitomycin formulation, currently used as adjuvant treatment, in the upper urinary tract is approximately five minutes, compared to approximately six hours when mitomycin is formulated with RTGel ;

##TABLE_END ##TABLE_START

administering higher doses of an active drug th...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

URGN_OUT_35 [2025-04-28 14:28:50 -0400] 7272 Bytes | 2019 tokens | Cum: 8182 tkns (102.28% of 8k)
==========================================================================

This is our set of metrics for UroGen Pharma.
Please analyze the numbers.

+---------------------+-----------------------+--------------------------+------------------------+
| Volume: 1,107,897 | Perf Month: -1.09% | Option/Short: Yes / Yes | Sales Y/Y TTM: 9.29% |
+---------------------+-----------------------+--------------------------+------------------------+
| Avg Volume: 423.02K | Perf Quarter: 8.06% | Short Float: 13.24% | ROE: - |
+---------------------+-----------------------+--------------------------+------------------------+
| Rel Volume: 3.55 | Index: RUT | Short Ratio: 11.96 | ROI: -110.73% |
+---------------------+-----------------------+--------------------------+------------------------+
| RSI (14): 58.71 | Market Cap: 522.00M | Short Interest: 5.06M | Sales Surprise: -4.17% |
+---------------------+-----------------------+--------------------------+------------------------+
| ATR (14): 0.72 | Shs Outstand: 42.23M | Beta: 0.70 | EPS Surprise: -11.16% |
+---------------------+-----------------------+--------------------------+------------------------+
| SMA20: 10.20% | Shs Float: 38.22M | Sales Q/Q: 4.40% | P/E: - |
+---------------------+-----------------------+--------------------------+------------------------+
| SMA50: 7.92% | Inst Own: 80.50% | Sales past 5Y: 13165.79% | Earnings: Mar 10 BMO |
+---------------------+-----------------------+--------------------------+------------------------+
| SMA200: -7.13% | Insider Own: 17.09% | Employees: 235 | |
+---------------------+-----------------------+--------------------------+------------------------+
| Perf Week: 17.23% | Insider Trans: -0.15% | Debt/Eq: - | |
+---------------------+-----------------------+--------------------------+------------------------+

The next section covers any insider trading by UroGen Pharma officers or majority shareholders (if available).

Inside Trans: UroGen Pharma Ltd. (URGN) by Barrett Elizabeth A. (Chief Executive Officer) on 2025-01-31
- Restricted Stock Units: 96377 shares at $0 (D)

Inside Trans: UroGen Pharma Ltd. (URGN) by Smith Jason Drew (General Counsel) on 2025-01-31
- Ordinary Shares: 2500 shares at $N/A (D)
- Ordinary Shares: 1258 shares at $11.14 (D)
- Ordinary Shares: 6667 shares at $N/A (D)
- Ordinary Shares: 3354 shares at $11.14 (D)
- Ordinary Shares: 5500 shares at $N/A (D)
- Ordinary Shares: 2767 shares at $11.14 (D)
- Restricted Stock Units: 2500 shares at $0 (D)
- Restricted Stock Units: 6667 shares at $0 (D)
- Restricted Stock Units: 5500 shares at $0 (D)
- Restricted Stock Units: 10000 shares at $0 (D)

Inside Trans: UroGen Pharma Ltd. (URGN) by Schoenberg Mark (Chief Medical Officer) on 2025-01-31
- Ordinary Shares: 1334 shares at $N/A (D)
- Ordinary Shares: 759 shares at $11.14 (D)
- Ordinary Shares: 3333 shares at $N/A (D)
- Ordinary Shares: 1896 shares at $11.14 (D)
- Ordinary Shares: 3333 shares at $N/A (D)
- Ordinary Shares: 1896 shares at $11.14 (D)
- Restricted Stock Units: 1334 shares at $0 (D)
- Restricted Stock Units: 3333 shares at $0 (D)
- Restricted Stock Units: 3333 shares at $0 (D)
- Restricted Stock Units: 20000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 90398000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -126874000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 11.51
Average Volume: 568841.45
30-Day High: 11.51
30-Day Low: 9.39

[Detailed Financials: TTM 2024]
- Total Assets: $285,711,000.00
- Total Liabilities: $294,514,000.00
- Total Equity: $-8,803,000.00
- Current Assets: $276,135,000.00
- Current Liabilities: $45,949,000.00

[Income Statement: TTM 2024]
- Revenue: $90,398,000.00
- Net Income: $-126,874,000.00
- Gross Profit: $81,517,000.00
- Operating Income: $-96,782,000.00
- Earnings Per Share (EPS): -2.96

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $77,240,000.00

[Detailed Financials: FY 2024]
- Total Assets: $285,711,000.00
- Total Liabilities: $294,514,000.00
- Total Equity: $-8,803,000.00
- Current Assets: $276,135,000.00
- Current Liabilities: $45,949,000.00

[Income Statement: FY 2024]
- Revenue: $90,398,000.00
- Net Income: $-126,874,000.00
- Gross Profit: $81,517,000.00
- Operating Income: $-96,782,000.00
- Earnings Per Share (EPS): -2.96

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $77,240,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of UroGen Pharma (URGN).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about UroGen Pharma.

2) MARKET_SCORE[]
This conversation was initiated because URGN is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for URGN.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, URGN could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect URGN to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of UroGen Pharma.

11) ETHICAL_RATING[]
Rate UroGen Pharma’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of UroGen Pharma.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

URGN_IN_37 [2025-04-28 14:28:51 -0400] 126 Bytes | 29 tokens | Cum: 8413 tkns (105.16% of 8k)
==========================================================================

====================================
[2025-04-28 14:28:51] # Analysis Completed
Elapsed Time: 51.78 seconds